Summary：Alpha Cognition Delivers Exciting Insights at B. Riley Summit on Mind, Muscle & Vision VANCOUVER, B

Alpha Cognition Delivers Exciting Insights at B. Riley Summit on Mind, Muscle & Vision

VANCOUVER, British Columbia & DALLAS — Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical firm dedicated to creating novel therapies for debilitating neurodegenerative disorders, today announced that Michael McFadden, Chief Scientific Officer, presented compelling preclinical data at the B. Riley Summit on Mind, Muscle & Vision. The summit, held virtually on November 12, gathered leading neuroscientists, clinicians, and investors to discuss breakthroughs linking cognitive health, muscular function, and visual processing.

**Key Developments**
During his 20‑minute talk, McFadden highlighted Alpha Cognition’s lead asset, ACG‑101, a small‑molecule modulator targeting the synaptic protein PSD‑95. In transgenic mouse models of Alzheimer’s disease, ACG‑101 restored long‑term potentiation and improved